Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Cancer
    January 2024
  1. MUTCH D, Voulgari A, Chen XM, Bradley WH, et al
    Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
    Cancer. 2024 Jan 30. doi: 10.1002/cncr.35222.
    >> Share

  2. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    >> Share

    December 2023
  3. LUMISH MA, Kohn EC, Tew WP
    Top advances of the year: Ovarian cancer.
    Cancer. 2023 Dec 15. doi: 10.1002/cncr.35135.
    >> Share

    November 2023
  4. HINCHCLIFF EM, Knisely A, Adjei N, Fellman B, et al
    Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
    Cancer. 2023 Nov 27. doi: 10.1002/cncr.35126.
    >> Share

    October 2023
  5. PARK S, Kim YJ, Min YJ, Mortimer PGS, et al
    Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059.
    >> Share

    September 2023
  6. NIERENGARTEN MB
    New standard of care for platinum-resistant ovarian cancer.
    Cancer. 2023;129:2601-2602.
    >> Share

    July 2023
  7. WHITE VM, Alexiadis M, Eroh KD, Ackermann MK, et al
    How social media can help to understand treatment experiences of survivors of rare cancers: Findings from the Granulosa Cell Tumor Survivor Sisters Facebook group member survey.
    Cancer. 2023;129:2224-2234.
    >> Share

    June 2023
  8. GRISHAM RN, Manning-Geist BL, Chui MH
    The highs and lows of serous ovarian cancer.
    Cancer. 2023 Jun 27. doi: 10.1002/cncr.34903.
    >> Share

  9. MEDINA HN, Penedo FJ, Joachim C, Deloumeaux J, et al
    Endometrial cancer risk and trends among distinct African descent populations.
    Cancer. 2023 Jun 26. doi: 10.1002/cncr.34789.
    >> Share

  10. MIRZA MR, Gonzalez-Martin A, Graybill WS, O'Malley DM, et al
    Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Cancer. 2023;129:1846-1855.
    >> Share

    May 2023
  11. KINDLER HL, Yoo HK, Hettle R, Cui KY, et al
    Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Cancer. 2023;129:1411-1418.
    >> Share

    March 2023
  12. MANNING-GEIST BL, Kahn RM, Nemirovsky D, Girshman J, et al
    Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34753.
    >> Share

  13. FOSTER KI, Shaw KRM, Jin J, Westin SN, et al
    Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
    Cancer. 2023 Mar 17. doi: 10.1002/cncr.34724.
    >> Share

  14. METCALFE KA, Gronwald J, Tung NM, McCuaig JM, et al
    The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
    Cancer. 2023;129:901-907.
    >> Share

  15. GRISHAM RN, Manning-Geist BL, Chui MH
    Beyond the estrogen receptor: In search of predictive biomarkers for low-grade serous ovarian cancer.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34658.
    >> Share

  16. HENDRIKSE CSE, van der Ploeg P, van de Kruis NMA, Wilting JHC, et al
    Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34661.
    >> Share

    December 2022
  17. KANG EY, Weir A, Meagher NS, Farrington K, et al
    CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
    Cancer. 2022 Dec 26. doi: 10.1002/cncr.34582.
    >> Share

    October 2022
  18. LUTGENDORF SK, Thaker PH, Goodheart MJ, Arevalo JMG, et al
    Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.
    Cancer. 2022 Oct 17. doi: 10.1002/cncr.34496.
    >> Share

  19. O'ROURKE K
    First person profile: Robert C. Bast Jr MD: As an ovarian cancer expert, Dr Bast has made history by identifying cancer antigen 125, and he has shared his knowledge by mentoring the next generation of physicians: As an ovarian cancer expert, Dr Bast h
    Cancer. 2022;128:3431-3432.
    >> Share

    June 2022
  20. MARTH C, Abreu MH, Andersen KK, Aro KM, et al
    Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
    Cancer. 2022 Jun 17. doi: 10.1002/cncr.34350.
    >> Share

    January 2022
  21. ARUN BK, Peterson SK, Sweeney LE, Bluebond RD, et al
    Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Cancer. 2022;128:94-102.
    >> Share

    December 2021
  22. MCBRIDE CM, Pathak S, Johnson CE, Alberg AJ, et al
    Psychosocial factors associated with genetic testing status among African American women with ovarian cancer: Results from the African American Cancer Epidemiology Study.
    Cancer. 2021 Dec 9. doi: 10.1002/cncr.34053.
    >> Share

  23. MOMTAZ P, O'Connor CA, Chou JF, Capanu M, et al
    Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    Cancer. 2021;127:4393-4402.
    >> Share

    November 2021
  24. TEMKIN SM, Smeltzer MP, Dawkins MD, Boehmer LM, et al
    Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations.
    Cancer. 2021 Nov 17. doi: 10.1002/cncr.34023.
    >> Share

    October 2021
  25. NIERENGARTEN MB
    Rucaparib is a safe and effective maintenance therapy for advanced pancreatic cancer.
    Cancer. 2021;127:3498.
    >> Share

    September 2021
  26. KOTSOPOULOS J, Kim SJ, Armel S, Bordeleau L, et al
    An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    Cancer. 2021;127:3183-3193.
    >> Share

    August 2021
  27. HUEPENBECKER SP, Sun CC, Fu S, Zhao H, et al
    Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States.
    Cancer. 2021 Aug 4. doi: 10.1002/cncr.33829.
    >> Share

    June 2021
  28. MAKHNOON S, Tran G, Levin B, Mattie KD, et al
    Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33668.
    >> Share

    May 2021
  29. KIM SR, Tone A, Kim RH, Cesari M, et al
    Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    Cancer. 2021 May 13. doi: 10.1002/cncr.33625.
    >> Share

    March 2021
  30. LEE CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, et al
    Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Cancer. 2021 Mar 19. doi: 10.1002/cncr.33517.
    >> Share

    February 2021
  31. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Trends and racial disparities in aggressive end-of-life care for a national sample of women with ovarian cancer.
    Cancer. 2021 Feb 25. doi: 10.1002/cncr.33488.
    >> Share

  32. MUKAMA T, Kharazmi E, Sundquist K, Sundquist J, et al
    Risk-adapted starting age of breast cancer screening in women with a family history of ovarian or other cancers: A nationwide cohort study.
    Cancer. 2021 Feb 23. doi: 10.1002/cncr.33456.
    >> Share

  33. SIMON MS, Hastert TA, Barac A, Banack HR, et al
    Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative.
    Cancer. 2021;127:598-608.
    >> Share

    December 2020
  34. PRINTZ C
    Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says.
    Cancer. 2020;126:5007.
    >> Share

    July 2020
  35. LUTGENDORF SK, Penedo F, Goodheart MJ, Dahmoush L, et al
    Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.
    Cancer. 2020 Jul 21. doi: 10.1002/cncr.33060.
    >> Share

    May 2020
  36. POORT H, de Rooij BH, Uno H, Weng S, et al
    Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study.
    Cancer. 2020 May 21. doi: 10.1002/cncr.32927.
    >> Share

    April 2020

  37. The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms.
    Cancer. 2020 Apr 13. doi: 10.1002/cncr.32867.
    >> Share

    March 2020
  38. RUSSO M, Newell JM, Budurlean L, Houser KR, et al
    Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.
    Cancer. 2020 Mar 18. doi: 10.1002/cncr.32822.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016